FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.
You may also be interested in...
PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications
Success of review model for new molecular entities and novel biologics should bolster US FDA and industry's stance that Congress reauthorize the user fee program without tinkering with the negotiated agreement, which retains the 'Program' but builds in more flexibility.
FDA Continues To Speed PD-1/L1 Drugs To Market
The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.
FDA Outlines “Expedited” Review For Breakthrough Therapies; “Hyper-Fast” Reviews, Beyond Oncology
Oncology drug sponsors have gotten used to a “faster-than-Priority” timeline for breakthrough products. Now, FDA is outlining a formal process for its reviewers to use for any “Breakthrough” designated therapy with life-saving potential.